| Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance SM Shaffer, MC Dunagin, SR Torborg, EA Torre, B Emert, C Krepler, ... Nature 546 (7658), 431-435, 2017 | 1144 | 2017 |
| Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study C Robert, A Ribas, J Schachter, A Arance, JJ Grob, L Mortier, A Daud, ... The Lancet Oncology 20 (9), 1239-1251, 2019 | 1081 | 2019 |
| Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells A Roesch, A Vultur, I Bogeski, H Wang, KM Zimmermann, D Speicher, ... Cancer cell 23 (6), 811-825, 2013 | 703 | 2013 |
| Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy Y Zhang, R Kurupati, L Liu, XY Zhou, G Zhang, A Hudaihed, F Filisio, ... Cancer cell 32 (3), 377-391. e9, 2017 | 485 | 2017 |
| Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a … AMM Eggermont, M Kicinski, CU Blank, M Mandala, GV Long, V Atkinson, ... JAMA oncology 6 (4), 519-527, 2020 | 359 | 2020 |
| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The Lancet Oncology 22 (5), 643-654, 2021 | 331 | 2021 |
| Targeting the ATR/CHK1 Axis with PARP Inhibition Results in Tumor Regression in BRCA-Mutant Ovarian Cancer Models H Kim, E George, RL Ragland, S Rafail, R Zhang, C Krepler, MA Morgan, ... Clinical Cancer Research 23 (12), 3097-3108, 2017 | 271 | 2017 |
| Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors G Zhang, DT Frederick, L Wu, Z Wei, C Krepler, S Srinivasan, YC Chae, ... The Journal of clinical investigation 126 (5), 1834-1856, 2016 | 266 | 2016 |
| Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial AMM Eggermont, CU Blank, M Mandala, GV Long, VG Atkinson, S Dalle, ... Journal of clinical oncology 38 (33), 3925-3936, 2020 | 252 | 2020 |
| Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma J Villanueva, JR Infante, C Krepler, P Reyes-Uribe, M Samanta, HY Chen, ... Cell reports 4 (6), 1090-1099, 2013 | 222 | 2013 |
| An integrated model of RAF inhibitor action predicts inhibitor activity against oncogenic BRAF signaling Z Karoulia, Y Wu, TA Ahmed, Q Xin, J Bollard, C Krepler, X Wu, C Zhang, ... Cancer cell 30 (3), 485-498, 2016 | 179 | 2016 |
| PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas H Lu, S Liu, G Zhang, B Wu, Y Zhu, DT Frederick, Y Hu, W Zhong, ... Nature 550 (7674), 133-136, 2017 | 168 | 2017 |
| The mitogen-activated protein kinase pathway in melanoma part I–activation and primary resistance mechanisms to BRAF inhibition T Amaral, T Sinnberg, F Meier, C Krepler, M Levesque, H Niessner, ... European journal of cancer 73, 85-92, 2017 | 156 | 2017 |
| A stress-induced early innate response causes multidrug tolerance in melanoma D Ravindran Menon, S Das, C Krepler, A Vultur, B Rinner, S Schauer, ... Oncogene 34 (34), 4448-4459, 2015 | 141 | 2015 |
| Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy R Somasundaram, T Connelly, R Choi, H Choi, A Samarkina, L Li, ... Nature communications 12 (1), 346, 2021 | 139 | 2021 |
| BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth T Wang, M Xiao, Y Ge, C Krepler, E Belser, A Lopez-Coral, X Xu, G Zhang, ... Clinical cancer research 21 (7), 1652-1664, 2015 | 138 | 2015 |
| A comprehensive patient-derived xenograft collection representing the heterogeneity of melanoma C Krepler, K Sproesser, P Brafford, M Beqiri, B Garman, M Xiao, ... Cell reports 21 (7), 1953-1967, 2017 | 137 | 2017 |
| Tumor-associated B-cells induce tumor heterogeneity and therapy resistance R Somasundaram, G Zhang, M Fukunaga-Kalabis, M Perego, C Krepler, ... Nature communications 8 (1), 607, 2017 | 132 | 2017 |
| Personalized preclinical trials in BRAF inhibitor–resistant patient-derived xenograft models identify second-line combination therapies C Krepler, M Xiao, K Sproesser, PA Brafford, B Shannan, M Beqiri, Q Liu, ... Clinical Cancer Research 22 (7), 1592-1602, 2016 | 131 | 2016 |
| MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines A Vultur, J Villanueva, C Krepler, G Rajan, Q Chen, M Xiao, L Li, ... Oncogene 33 (14), 1850-1861, 2014 | 113 | 2014 |
